Citizens Jmp Upgrades Ironwood Pharmaceuticals (NASDAQ:IRWD) to Market Outperform

Ironwood Pharmaceuticals (NASDAQ:IRWD) was upgraded by stock analysts at Citizens Jmp from a “market perform” rating to a “market outperform” rating in a report issued on Monday, Marketbeat.com reports. The firm currently has a $8.00 target price on the biotechnology company’s stock. Citizens Jmp’s price target points to a potential upside of 86.05% from the company’s previous close.

Other research analysts have also issued reports about the stock. Weiss Ratings reaffirmed a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Zacks Research upgraded Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Thursday, January 1st. Citigroup raised Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday. Finally, Wells Fargo & Company raised their price target on Ironwood Pharmaceuticals from $1.00 to $3.00 and gave the stock an “equal weight” rating in a report on Tuesday, November 11th. Two equities research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average target price of $6.12.

Ironwood Pharmaceuticals Trading Down 6.3%

IRWD stock opened at $4.30 on Monday. The firm has a market cap of $699.52 million, a P/E ratio of 26.88 and a beta of 0.18. Ironwood Pharmaceuticals has a 12-month low of $0.53 and a 12-month high of $5.78. The stock’s 50 day simple moving average is $3.17 and its 200 day simple moving average is $1.85.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its quarterly earnings data on Monday, November 10th. The biotechnology company reported $0.24 EPS for the quarter, topping analysts’ consensus estimates of $0.09 by $0.15. Ironwood Pharmaceuticals had a net margin of 8.70% and a negative return on equity of 15.17%. The firm had revenue of $122.06 million during the quarter, compared to the consensus estimate of $74.22 million. On average, research analysts forecast that Ironwood Pharmaceuticals will post 0.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several hedge funds and other institutional investors have recently made changes to their positions in IRWD. Jacobs Levy Equity Management Inc. grew its holdings in Ironwood Pharmaceuticals by 30.2% in the 3rd quarter. Jacobs Levy Equity Management Inc. now owns 1,920,530 shares of the biotechnology company’s stock worth $2,516,000 after buying an additional 445,484 shares in the last quarter. Public Employees Retirement System of Ohio boosted its position in Ironwood Pharmaceuticals by 351.2% during the 3rd quarter. Public Employees Retirement System of Ohio now owns 60,768 shares of the biotechnology company’s stock worth $80,000 after acquiring an additional 47,299 shares during the period. Mercer Global Advisors Inc. ADV grew its stake in shares of Ironwood Pharmaceuticals by 113.5% in the third quarter. Mercer Global Advisors Inc. ADV now owns 71,353 shares of the biotechnology company’s stock worth $93,000 after purchasing an additional 37,938 shares in the last quarter. Millennium Management LLC grew its stake in shares of Ironwood Pharmaceuticals by 159.6% in the third quarter. Millennium Management LLC now owns 250,119 shares of the biotechnology company’s stock worth $328,000 after purchasing an additional 153,787 shares in the last quarter. Finally, Integrated Wealth Concepts LLC increased its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 3,406 shares during the period.

Ironwood Pharmaceuticals News Roundup

Here are the key news stories impacting Ironwood Pharmaceuticals this week:

• Positive Sentiment: Ironwood issued upbeat FY‑2026 guidance projecting roughly $450–$475M in revenue and adjusted EBITDA north of $300M, a sizeable beat versus prior consensus — management attributes the improvement to a strategic LINZESS list‑price reset that reduces rebate penalties and materially improves net margins. This guidance underpins management’s claim it can self‑fund the apraglutide Phase 3 program. Ironwood press release
• Positive Sentiment: Analysts reacted quickly with upgrades and higher targets — Craig Hallum moved IRWD to “strong-buy,” Citizens JMP upgraded to “market outperform” and set an $8 target, and Wells Fargo raised its target from $3 to $5 — these changes bring more buy-side support and raise the stock’s upside narrative. Citizens upgrade (MSN) Craig Hallum / Zacks note Wells Fargo / Benzinga
• Positive Sentiment: Market reaction: several outlets reported sharp intraday moves (reports cite ~20–30% rallies earlier in the week) after the guidance — that price action reflects the market repricing Ironwood from a cash‑constrained biotech to a self‑funded commercial business in 2026. Zacks coverage of the move
• Neutral Sentiment: Coverage and analysis pieces (AAII, Kalkine) explain the mechanical drivers (rebate math, pricing, pipeline timing) and provide trading/flow context; these help inform sentiment but don’t change fundamentals by themselves. AAII article Kalkine media
• Negative Sentiment: Risks remain: the apraglutide confirmatory Phase 3 still must be executed successfully and long‑term exposure to generic competition (post‑patent expiry) and regulatory/operational execution could reduce upside — the guidance reduces near‑term cash risk but does not eliminate clinical or competitive risk. Company guidance & risk discussion

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals, Inc is a commercial‐stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.